Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: web + 0.14  Related to the article below (Last Update: 8/4/2008)


Earthtimes (press release)
Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
Actuate Reports Second Quarter 2008 Financial Results MarketWatch
Sonic Foundry Reports Third Quarter 2008 Results IT News Online
Conexant Reports Financial Results for the Third Quarter of Fiscal ... Trading Markets (press release)
PR Newswire (press release)
all 733 news articles »  SOFO - THOR - CNXTD

ZDNet
How I Learned to Stop Worrying and Love Windows Vista. NOT!
ZDNet -
Granted, her older box used Firefox 2.0.0.14 and the new one 3.0, but when I regression tested 3.0 as the default browser on my own XP systems and with the ...
Triad Guaranty Inc. Reports Second Quarter Loss as Reported ...
MarketWatch -
For more information, please visit the Company's web site at www.triadguaranty.com. Diluted realized investment gains (losses) per share, net of taxes, ...TGIC

RTT News
athenahealth, Inc. Reports Second Quarter 2008 Results
WELT ONLINE, Germany -
A live webcast and replay will also be available shortly after the call is completed on the Company's investor web site: ...
TheStreet.com Reports Second-Quarter Financial Results MarketWatch
ScottsMiracle-Gro Announces Record Third Quarter Sales Based on ... PR Newswire (press release)
LoopNet, Inc. Announces Second Quarter 2008 Financial Results Trading Markets (press release)
all 494 news articles »  LOOP - ATHN - TSCM
Boots & Coots Reports Second Quarter and Six Month Results
MarketWatch -
... to these forward-looking statements are found in Boots & Coots' SEC filings, which are available free of charge on the SEC's web site at www.sec.gov. ...WEL
Six Flags Announces Second Quarter Results
CNNMoney.com (press release) -
The teleconference will be broadcast live to all interested persons as a listen-only Web cast on http://investors.sixflags.com/. The Web cast will be ...SIX

Earthtimes (press release)
ADP Reports Fiscal 2008 Results; Provides Fiscal 2009 Guidance
Trading Markets (press release), CA - Jul 31, 2008
ADP's news releases, current financial information, SEC filings and Investor Relations presentations are accessible at the same Web site. ...
Chicopee Bancorp, Inc. Reports Second Quarter Results FOXBusiness
Cascade Microtech Reports Second Quarter 2008 Results Trading Markets (press release)
all 1,003 news articles »  CSCD - ADP - CBNK
Nexity Financial Second Quarter Results
Trading Markets (press release), CA - Jul 31, 2008
Webcast: Live via the Internet and Windows Media Player http://www.nexitybank.com/ then to the Investor Relations section, to conference in via the web Then ...NXTY

WELT ONLINE
Susquehanna Bancshares, Inc. Announces Second Quarter Results
WELT ONLINE, Germany - Jul 23, 2008
Net charge-offs as a percentage of average loans and leases for the quarter ended June 30, 2008 were 0.48% compared to 0.14% for the second quarter of 2007. ...
First Security Group Announces Earnings MarketWatch
West Coast Bancorp Reports 2008 Second Quarter Earnings Earthtimes (press release)
Tower Financial Corporation Reports Earnings of $0.08 Per Share Primenewswire (press release)
MarketWatch - MarketWatch
all 1,034 news articles »  TOFC - SNV - SUSQ
NMS Communications Announces Financial Results for the Second ...
Business Wire (press release), CA - Jul 31, 2008
Non-GAAP loss from continuing operations was $(6.3) million, or $(0.14) per share, for the second quarter of 2008, compared to a non-GAAP loss from ...NMSS
Source: Google News

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
... bank in- depen- dence" (index) 0.33 0.33 0.31 0.30 0.30 0.30 0.29 0.29 0.27 0.27
0.27 0.27 0.25 0.24 0.24 0.22 0.21 0.21 0.21 0.20 0.20 0.18 0.17 0.14 0.10 ...

[PDF] Data Preparation for Mining World Wide Web Browsing Patterns -
R Cooley, B Mobasher, J Srivastava? - Knowledge and Information Systems, 1999 - mis.ncyu.edu.tw
Page 1. Data Preparation for Mining World Wide Web Browsing Patterns ... An important
input to these design tasks is the analysis of how a Web site is being used. ...

Measuring web site quality improvements: a case study of the forum on strategic management knowledge … -
SJ Barnes, R Vidgen - Industrial Management & Data Systems, 2003 - emeraldinsight.com
... [ 302 ] Stuart J. Barnes and Richard Vidgen Measuring Web site quality improvements:
a case study of the forum on strategic management knowledge exchange ... 0.14 ...

… of silver carp Hypophthalmichthys molitrix Val. and its impact on the food web in Lake Kinneret, … -
P Spataru, M Gophen - Hydrobiologia, 1985 - Springer
... and its impact on the food web in Lake Kinneret, Israel ... 2 0.37 0.04 0.71 3 1 .05
11 14.04 3 1 .42 0.14 0.26 5 0.35 3 8 .14 4 0.11 0.01 0.01 0.14 0 0 0.15 ...

Classification of Web documents using a naive Bayes method -
Y Wang, J Hodges, B Tang - Tools with Artificial Intelligence, 2003. Proceedings. 15th …, 2003 - ieeexplore.ieee.org
... For example, in [13], the total number of categories used by Quek?s web document
classification ... MB MN MB MN MB MN 0 0.14 0.14 1 1 0.25 0.25 0.1 0.17 0.3 0.87 ...

Harvesting implicit group attitudes and beliefs from a demonstration web site -
BA Nosek, MR Banaji, AG Greenwald - Group Dynamics: Theory, Research, and Practice, 2002 - content.apa.org
... 63 ms (d 0.28); conservative set: face 26 ms (d 0.12), name 29 ms (d 0.14). ... Explicit
Attitudes for Each of the Nine Tasks Available at the IAT Web Site Between ...

Real life information retrieval: a study of user queries on the Web -
BJ Jansen, A Spink, J Bateman, T Saracevic - ACM SIGIR Forum, 1998 - portal.acm.org
... But in any case, this, of course, has interesting implications for recall and may
illustrate a need for high precision in Web IR algorithms ... 15 25 0.14 50 2 0.01 ...

[PDF] An Adaptive Agent for Web Exploration Based on Concept Hierarchies -
S Parent, B Mobasher, S Lytinen - Proceedings of the 9th International Conference on Human …, 2001 - maya.cs.depaul.edu
... On the other hand, a user interested in searching the Web for specific medical ... music:
1.000 blue: 0.15 new: 0.14 artist: 0.13 jazz: 0.12 review: 0.12 band ...

The influence of browsers on evaluators or, continuations to program web servers -
C Queinnec - Proceedings of the fifth ACM SIGPLAN international …, 2000 - portal.acm.org
... 2.3 Web computation q? !vG?$? ?2" ? 4&s?$&? cf ???X 7 G !vH cf ? ?g ... If
1 FRF corresponds to 0.14 $ then 3 FRF corresponds to 0.42 $. ...

[PDF] Phylogenetic constraints and adaptation explain food-web structure -
MF Cattin, LF Bersier, C Banasek-Richter, R … - Nature, 2004 - unifr.ch
... by one order of magnitude?in the prediction of these standard food-web descriptors. ...
T 0.06 [0.04] 0.08 0.05 [0] 0.03 0.10 [0] 0.10 0.14 [0.28] 0.15 0.08 [0.38 ...
-

Source: Google Scholar
 
 

Osteologix Initiates Phase II Clinical Trial Of Investigational Drug For Osteoporosis

Article Date: 07 Dec 2006 - 0:00am (PST)
Osteologix Inc. (OTC Bulletin Board: OLGX) announced today that it has initiated a randomized, double-blind, placebo-controlled phase II clinical trial of NB S101, its investigational drug for osteoporosis. The primary endpoint of the study is the change in patients' bone resorption. Osteologix plans to enroll approximately 275 postmenopausal women with low bone mineral density and treat them for 12 weeks in the clinical trial, which is being conducted at investigator sites located throughout the UK and Denmark.

"I am very pleased to be initiating this phase II study within only three years of the creation of Osteologix and initiation of NB S101 development. Our goal is to build further evidence of the efficacy and safety of NB S101 as a primary treatment for osteoporosis," stated Charles J. Casamento, CEO and President. "There is a significant need for improved osteoporosis treatments. We believe NB S101 may have the ability to both increase bone formation and decrease bone resorption, while also reducing the side effects most common in osteoporosis drugs available today, providing a tremendous potential opportunity for Osteologix."

Article continues below and (thank you)

 
The clinical trial being initiated by Osteologix, "A dose-response study with strontium malonate in healthy post-menopausal women," is designed with five randomized arms. The company plans to enroll approximately 55 patients in each arm. Four arms of the trial will be double-blind, including three different doses of NB S101 (750 mg, 1000 mg and 2000 mg) and placebo. The primary endpoint will be the effect of NB S101 on CTX-1, a biochemical marker of bone resorption. NB S101 is the Osteologix investigational drug containing strontium malonate as its active ingredient. In addition to the four double- blind arms, there will be an open-label arm containing Protelos (strontium ranelate, approved in Europe for the treatment of Osteoporosis). The Protelos arm is open-label because Protelos is only available in a sachet and must be mixed with water prior to ingestion. NB S101 is a once-daily tablet available with increased bioavailability of free strontium when compared to Protelos (strontium ranelate).

In addition to the primary endpoint of quantifying bone resorption, Osteologix plans to evaluate the effect of NB S101 on bone formation by measuring markers specific for this process. Other secondary endpoints being evaluated include the effects of NB S101 on bone mineral density, strontium levels and markers of cartilage degradation. Side effects will also be assessed.

About Osteologix

Osteologix develops proprietary therapeutics for the treatment of important unmet medical needs in bone disease and women's health. The Company's lead product, NB S101, has entered phase II clinical trials for the treatment of osteoporosis. Based on the Company's own data as well as data from phase III clinical trials conducted on another salt of strontium that is approved for sale in Europe, Osteologix believes that NB S101 increases new bone formation and decreases bone resorption. Osteologix further believes that NB S101 will provide patients with greater convenience and fewer side effects than drugs currently approved for osteoporosis in the United States, Europe and elsewhere, thereby addressing the need for an osteoporosis drug with higher compliance rates and better long term efficacy. The Company is not aware of any osteoporosis drug currently approved for sale in the United States that simultaneously increases bone formation and decreases bone resorption. Osteologix is committed to creating value by building a world- class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Osteologix can be obtained on the Company's website, http://www.osteologix.com.

FORWARD-LOOKING STATEMENTS:

Certain of the statements set forth in this press release constitute "Forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding Osteologix's research and development programs; proposed marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; and the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies. There can be no assurance that such forward-looking statements will prove to be accurate and Osteologix undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

Osteologix Inc.
http://www.osteologix.com
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9A ;